UA75365C2 - Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon - Google Patents

Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon Download PDF

Info

Publication number: UA75365C2
Authority: UA; Ukraine
Prior art keywords: temperature; hours; specified; mixture; crystalline
Prior art date: 2000-08-16

Application number

UA2003032259A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-16

Filing date

2001-01-08

Publication date

2006-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA75365(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2006-04-17 Publication of UA75365C2 publication Critical patent/UA75365C2/uk

Links

229930013356 epothilone Natural products 0.000 title claims abstract description 34
150000003883 epothilone derivatives Chemical class 0.000 title claims abstract description 32
238000000034 method Methods 0.000 title claims abstract description 21
238000012986 modification Methods 0.000 title claims description 28
230000004048 modification Effects 0.000 title claims description 28
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
239000000203 mixture Substances 0.000 claims abstract description 47
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 75
239000000725 suspension Substances 0.000 claims description 39
239000013078 crystal Substances 0.000 claims description 35
239000000243 solution Substances 0.000 claims description 26
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
230000015572 biosynthetic process Effects 0.000 claims description 9
239000011541 reaction mixture Substances 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
238000001069 Raman spectroscopy Methods 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 6
238000000354 decomposition reaction Methods 0.000 claims description 6
238000002844 melting Methods 0.000 claims description 6
230000008018 melting Effects 0.000 claims description 6
238000001228 spectrum Methods 0.000 claims description 6
238000001816 cooling Methods 0.000 claims description 5
230000002062 proliferating effect Effects 0.000 claims description 5
238000003756 stirring Methods 0.000 claims description 5
238000004090 dissolution Methods 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 2
238000001237 Raman spectrum Methods 0.000 claims 3
239000007864 aqueous solution Substances 0.000 claims 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
229920000053 polysorbate 80 Polymers 0.000 claims 2
229940068968 polysorbate 80 Drugs 0.000 claims 2
239000004480 active ingredient Substances 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
239000000945 filler Substances 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
239000002552 dosage form Substances 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
238000005516 engineering process Methods 0.000 description 13
238000004128 high performance liquid chromatography Methods 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
239000007787 solid Substances 0.000 description 9
-1 1-methyl-2-(2- methyl-4-thiazolyl)ethenyl Chemical group 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
229910003986 SicO Inorganic materials 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000000843 powder Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000741 silica gel Substances 0.000 description 5
229910002027 silica gel Inorganic materials 0.000 description 5
239000002904 solvent Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
239000003480 eluent Substances 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
230000006907 apoptotic process Effects 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
208000032467 Aplastic anaemia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
208000032612 Glial tumor Diseases 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
201000010208 Seminoma Diseases 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
201000002246 embryonal cancer Diseases 0.000 description 2
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
230000003394 haemopoietic effect Effects 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000012265 solid product Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
206010065040 AIDS dementia complex Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
206010001605 Alcohol poisoning Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000033135 Classic hairy cell leukemia Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
206010021074 Hypoplastic anaemia Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010023347 Keratoacanthoma Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
208000005890 Neuroma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
241000710960 Sindbis virus Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000025434 cerebellar degeneration Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000006841 macrolactonization reaction Methods 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026037 malignant tumor of neck Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000002346 musculoskeletal system Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000013014 purified material Substances 0.000 description 1
239000012264 purified product Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
208000017572 squamous cell neoplasm Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

UA2003032259A 2000-08-16 2001-01-08 Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon UA75365C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22559000P	2000-08-16	2000-08-16
PCT/US2001/024540 WO2002014323A2 (en)	2000-08-16	2001-08-01	Polymorphs of an epothilone analog

Publications (1)

Publication Number	Publication Date
UA75365C2 true UA75365C2 (en)	2006-04-17

Family

ID=22845469

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003032259A UA75365C2 (en)	2000-08-16	2001-01-08	Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon

Country Status (41)

Country	Link
US (4)	US6689802B2 (de)
EP (1)	EP1309597B1 (de)
JP (1)	JP5046467B2 (de)
KR (1)	KR100810342B1 (de)
CN (1)	CN1269821C (de)
AR (1)	AR034259A1 (de)
AT (1)	ATE366735T1 (de)
AU (2)	AU8108201A (de)
BG (1)	BG66132B1 (de)
BR (1)	BR0113234A (de)
CA (1)	CA2418109C (de)
CY (1)	CY1107758T1 (de)
CZ (1)	CZ305523B6 (de)
DE (1)	DE60129334T2 (de)
DK (1)	DK1309597T3 (de)
EE (1)	EE05273B1 (de)
ES (1)	ES2288518T3 (de)
GE (1)	GEP20053495B (de)
HR (1)	HRP20030190B1 (de)
HU (1)	HU229314B1 (de)
IL (2)	IL153993A0 (de)
IS (1)	IS2845B (de)
LT (1)	LT5138B (de)
LV (1)	LV13032B (de)
MX (1)	MXPA03001431A (de)
MY (1)	MY134129A (de)
NO (1)	NO328500B1 (de)
NZ (1)	NZ523722A (de)
PE (1)	PE20020290A1 (de)
PL (1)	PL205628B1 (de)
PT (1)	PT1309597E (de)
RO (1)	RO123296B1 (de)
RU (1)	RU2272039C2 (de)
SI (1)	SI21100B (de)
SK (1)	SK287876B6 (de)
TW (1)	TWI320040B (de)
UA (1)	UA75365C2 (de)
UY (1)	UY26886A1 (de)
WO (1)	WO2002014323A2 (de)
YU (1)	YU12103A (de)
ZA (1)	ZA200300522B (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1386922B1 (de)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) *	1999-02-24	2002-05-16	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) *	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
CA2434526C (en) *	2001-01-25	2011-11-01	Bristol Myers Squibb Company	Methods of administering epothilone analogs for the treatment of cancer
SK8552003A3 (en) *	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
IL156988A0 (en)	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
ATE554756T1 (de) *	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
RU2341260C2 (ru) *	2002-03-08	2008-12-20	Новартис Аг	Комбинации, включающие производные эпотилона и алкилирующие агенты
US7649006B2 (en) *	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) *	2002-08-23	2007-01-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) *	2004-05-18	2009-01-01	Franchini Miriam K	Nanoparticle dispersion containing lactam compound
EP1640004A1 (de) *	2004-09-24	2006-03-29	Schering Aktiengesellschaft	Verwendung von Epothilonen zur Behandlung von Knochenmetastasen und Knochentumoren oder Knochenkrebs
WO2006055742A1 (en) *	2004-11-18	2006-05-26	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
SI1817013T1 (sl)	2004-11-18	2008-12-31	Bristol Myers Squibb Co	Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
US20060121511A1 (en)	2004-11-30	2006-06-08	Hyerim Lee	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (de)	2004-12-23	2006-06-28	Schering Aktiengesellschaft	Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
EP2634252B1 (de)	2005-02-11	2018-12-19	University of Southern California	Verfahren zur Expression von Proteinen mit Disulfidbrücken
PT1698630E (pt) *	2005-03-03	2014-09-15	Alfa Wassermann Spa	Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
WO2006122408A1 (en)	2005-05-18	2006-11-23	Aegera Therapeutics Inc.	Bir domain binding compounds
US7693596B2 (en)	2005-12-14	2010-04-06	Dell Products L.P.	System and method for configuring information handling system integrated circuits
US7919108B2 (en) *	2006-03-10	2011-04-05	Cook Incorporated	Taxane coatings for implantable medical devices
US20080286325A1 (en) *	2006-01-05	2008-11-20	Med Institute, Inc.	Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) *	2006-03-10	2011-01-25	Cook Incorporated	Methods of manufacturing and modifying taxane coatings for implantable medical devices
CA2647565A1 (en)	2006-03-31	2007-10-18	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
US8008256B2 (en)	2006-05-01	2011-08-30	University Of Southern California	Combination therapy for treatment of cancer
BRPI0711591A2 (pt)	2006-05-16	2011-11-16	Aegera Therapeutics, Inc.	composto de ligação de domìnio bir da iap
CN101506217B (zh) *	2006-08-16	2012-09-05	诺瓦提斯公司	埃坡霉素b的晶型及在药物组合物中的用途
US8463852B2 (en) *	2006-10-06	2013-06-11	Oracle International Corporation	Groupware portlets for integrating a portal with groupware systems
WO2008103916A2 (en) *	2007-02-23	2008-08-28	The Trustees Of Columbia Univeristy In The City Of New York	Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (de)	2007-11-29	2009-06-03	Bayer Schering Pharma Aktiengesellschaft	Kombinationen mit einem Prostaglandin und Verwendungen davon
DE102007059752A1 (de)	2007-12-10	2009-06-18	Bayer Schering Pharma Aktiengesellschaft	Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (de)	2007-12-10	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Nanopartikel mit modifizierter Oberfläche
US8802394B2 (en)	2008-11-13	2014-08-12	Radu O. Minea	Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (de)	2009-01-27	2010-07-28	Bayer Schering Pharma Aktiengesellschaft	Stabile Polymerzusammensetzung mit einem Epothilon und einem amphiphilischen Blockpolymer
NZ602368A (en)	2010-02-12	2014-10-31	Pharmascience Inc	Iap bir domain binding compounds
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2011153221A1 (en) *	2010-06-01	2011-12-08	Plus Chemicals Sa	Solid state forms of ixabepilone
CA2858806A1 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of polypeptides
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2872894B1 (de)	2012-07-13	2019-04-17	Innate Pharma	Screening von konjugierten antikörpern
EP2916872B1 (de)	2012-11-09	2019-02-27	Innate Pharma	Kennungen für tgase-vermittelte konjugation
CN103183681B (zh) *	2013-03-06	2016-01-13	浙江海正药业股份有限公司	伊沙匹隆的新晶型及其制备方法
US10611824B2 (en)	2013-03-15	2020-04-07	Innate Pharma	Solid phase TGase-mediated conjugation of antibodies
WO2014202773A1 (en)	2013-06-20	2014-12-24	Innate Pharma	Enzymatic conjugation of polypeptides
KR20160042871A (ko)	2013-06-21	2016-04-20	이나뜨 파르마, 에스.아.	폴리펩티드의 효소적 콘쥬게이션
WO2019092148A1 (en)	2017-11-10	2019-05-16	Innate Pharma	Antibodies with functionalized glutamine residues
AU2021212305A1 (en)	2020-01-31	2022-08-11	Allarity Therapeutics Europe ApS	Methods for predicting ixabepilone responsiveness in cancer patients
CN112457320A (zh) *	2020-11-30	2021-03-09	湖北宏中药业股份有限公司	一种提高伊沙匹隆合成反应速率的方法
CN112409366A (zh) *	2020-11-30	2021-02-26	湖北宏中药业股份有限公司	一种伊沙匹隆二聚体的高收率制备方法
CN112375085A (zh) *	2020-11-30	2021-02-19	湖北宏中药业股份有限公司	一种伊沙匹隆反应液的高收率高纯度处理方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1000809A (en) *	1960-11-02	1965-08-11	James Oakes & Company Riddings	Pipe manufacture
DE2308418B2 (de) *	1972-06-21	1976-04-08	Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland)	Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (de) *	1973-01-29	1977-10-12
SE386365B (sv) *	1973-07-25	1976-08-09	L Brendling	Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) *	1986-10-15	1988-04-28	Smc Corp	二重管およびその連続製造法
DE3927569A1 (de) *	1989-08-21	1991-02-28	Fritz Egger Gmbh	Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) *	1989-12-01	1991-06-06	Baedje K H Meteor Gummiwerke	Schlauch
AU6431790A (en) *	1990-01-05	1991-08-05	Orscheln Co.	Flexible synthetic plastic conduit
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) *	1992-02-27	1993-09-02	Wolf Woco & Co Franz J	Koaxialrohr
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
DE59609305D1 (de)	1995-11-17	2002-07-11	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Herstellung
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
DE19636343C1 (de)	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
ATE267197T1 (de)	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (de)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
EP0975638B1 (de)	1997-02-25	2002-08-07	Gesellschaft für biotechnologische Forschung mbH (GBF)	Seitenkettenmodifizierte epothilone
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
DK1001951T3 (da)	1997-07-16	2002-12-23	Schering Ag	Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
DE19747580A1 (de)	1997-10-28	1999-04-29	Siemens Ag	Rangierfeld mit Anschlußleiste
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR20080016756A (ko)	1998-02-05	2008-02-21	노파르티스 아게	유기화합물 함유 조성물
US6194181B1 (en) *	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de)	1998-02-21	1999-08-26	Roland Man Druckmasch	Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
FR2775187B1 (fr)	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
AU5036999A (en)	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
AU5325699A (en) *	1998-08-12	2000-03-06	Proteus Inc.	Ribbed core dual wall structure
BR9916833A (pt)	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
RU2242229C2 (ru) *	1999-01-19	2004-12-20	Новартис Аг	Применение эпотилонов для лечения рака
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6605559B1 (en)	1999-09-29	2003-08-12	Daihatsu Motor Co., Ltd.	Dimethyl ether reforming catalyst
US6518421B1 (en)	2000-03-20	2003-02-11	Bristol-Myers Squibb Company	Process for the preparation of epothilone analogs
DE60225666T2 (de)	2001-01-25	2009-04-16	Bristol-Myers Squibb Co.	Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en)	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
US9317043B2 (en)	2013-12-19	2016-04-19	Google Inc.	Path based power generation control for an aerial vehicle

2001
- 2001-01-08 UA UA2003032259A patent/UA75365C2/uk unknown
- 2001-07-26 MY MYPI20013545 patent/MY134129A/en unknown
- 2001-08-01 BR BR0113234-2A patent/BR0113234A/pt active Search and Examination
- 2001-08-01 IL IL15399301A patent/IL153993A0/xx unknown
- 2001-08-01 DK DK01959536T patent/DK1309597T3/da active
- 2001-08-01 PL PL365610A patent/PL205628B1/pl unknown
- 2001-08-01 GE GE5091A patent/GEP20053495B/en unknown
- 2001-08-01 CA CA2418109A patent/CA2418109C/en not_active Expired - Lifetime
- 2001-08-01 SK SK134-2003A patent/SK287876B6/sk not_active IP Right Cessation
- 2001-08-01 AU AU8108201A patent/AU8108201A/xx active Pending
- 2001-08-01 HR HR20030190A patent/HRP20030190B1/xx not_active IP Right Cessation
- 2001-08-01 PT PT01959536T patent/PT1309597E/pt unknown
- 2001-08-01 DE DE60129334T patent/DE60129334T2/de not_active Expired - Lifetime
- 2001-08-01 ES ES01959536T patent/ES2288518T3/es not_active Expired - Lifetime
- 2001-08-01 EE EEP200300063A patent/EE05273B1/xx not_active IP Right Cessation
- 2001-08-01 RU RU2003106431/04A patent/RU2272039C2/ru active
- 2001-08-01 CZ CZ2003-418A patent/CZ305523B6/cs not_active IP Right Cessation
- 2001-08-01 RO ROA200300114A patent/RO123296B1/ro unknown
- 2001-08-01 EP EP01959536A patent/EP1309597B1/de not_active Expired - Lifetime
- 2001-08-01 MX MXPA03001431A patent/MXPA03001431A/es active IP Right Grant
- 2001-08-01 AU AU2001281082A patent/AU2001281082B2/en not_active Ceased
- 2001-08-01 YU YU12103A patent/YU12103A/sh unknown
- 2001-08-01 CN CNB018170641A patent/CN1269821C/zh not_active Expired - Lifetime
- 2001-08-01 WO PCT/US2001/024540 patent/WO2002014323A2/en not_active Ceased
- 2001-08-01 AT AT01959536T patent/ATE366735T1/de active
- 2001-08-01 SI SI200120055A patent/SI21100B/sl not_active IP Right Cessation
- 2001-08-01 NZ NZ523722A patent/NZ523722A/en not_active IP Right Cessation
- 2001-08-01 HU HU0300826A patent/HU229314B1/hu not_active IP Right Cessation
- 2001-08-01 KR KR1020037002256A patent/KR100810342B1/ko not_active Expired - Fee Related
- 2001-08-01 JP JP2002519462A patent/JP5046467B2/ja not_active Expired - Fee Related
- 2001-08-09 US US09/925,112 patent/US6689802B2/en not_active Ceased
- 2001-08-10 TW TW090119585A patent/TWI320040B/zh not_active IP Right Cessation
- 2001-08-15 UY UY26886A patent/UY26886A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103901A patent/AR034259A1/es not_active Application Discontinuation
- 2001-08-16 PE PE2001000818A patent/PE20020290A1/es not_active Application Discontinuation
2003
- 2003-01-16 BG BG107467A patent/BG66132B1/bg unknown
- 2003-01-16 IL IL153993A patent/IL153993A/en not_active IP Right Cessation
- 2003-01-20 ZA ZA200300522A patent/ZA200300522B/en unknown
- 2003-02-11 IS IS6714A patent/IS2845B/is unknown
- 2003-02-14 NO NO20030707A patent/NO328500B1/no not_active IP Right Cessation
- 2003-02-25 LT LT2003017A patent/LT5138B/lt not_active IP Right Cessation
- 2003-03-07 LV LVP-03-28A patent/LV13032B/en unknown
2004
- 2004-02-06 US US10/773,819 patent/US6982276B2/en not_active Expired - Lifetime
2005
- 2005-03-09 US US11/076,589 patent/USRE39251E1/en not_active Expired - Lifetime
- 2005-11-10 US US11/271,456 patent/US7153879B2/en not_active Expired - Lifetime
2007
- 2007-10-11 CY CY20071101304T patent/CY1107758T1/el unknown

Also Published As

Publication number	Publication date
JP5046467B2 (ja)	2012-10-10
HU229314B1 (en)	2013-10-28
EP1309597A2 (de)	2003-05-14
US20060063815A1 (en)	2006-03-23
LT5138B (lt)	2004-06-25
BG107467A (bg)	2003-09-30
EE200300063A (et)	2004-12-15
KR100810342B1 (ko)	2008-03-07
BR0113234A (pt)	2004-02-25
NZ523722A (en)	2005-04-29
HRP20030190A2 (en)	2003-04-30
SK1342003A3 (en)	2003-09-11
KR20030022411A (ko)	2003-03-15
DE60129334T2 (de)	2008-04-03
CZ2003418A3 (cs)	2004-01-14
ES2288518T3 (es)	2008-01-16
YU12103A (sh)	2006-08-17
SK287876B6 (sk)	2012-02-03
EP1309597B1 (de)	2007-07-11
CZ305523B6 (cs)	2015-11-18
HUP0300826A2 (hu)	2003-09-29
PT1309597E (pt)	2007-08-22
HUP0300826A3 (en)	2005-05-30
RU2272039C2 (ru)	2006-03-20
NO20030707D0 (no)	2003-02-14
JP2004506638A (ja)	2004-03-04
SI21100B (sl)	2009-12-31
US20040157897A1 (en)	2004-08-12
AR034259A1 (es)	2004-02-18
PL205628B1 (pl)	2010-05-31
LT2003017A (en)	2004-03-25
RO123296B1 (ro)	2011-06-30
HK1052010A1 (en)	2003-08-29
CN1468243A (zh)	2004-01-14
UY26886A1 (es)	2002-03-22
NO20030707L (no)	2003-04-15
BG66132B1 (bg)	2011-06-30
US6689802B2 (en)	2004-02-10
US20020188014A1 (en)	2002-12-12
IL153993A (en)	2009-07-20
MY134129A (en)	2007-11-30
EE05273B1 (et)	2010-02-15
PE20020290A1 (es)	2002-04-03
ZA200300522B (en)	2004-04-20
IL153993A0 (en)	2003-07-31
US6982276B2 (en)	2006-01-03
TWI320040B (en)	2010-02-01
AU8108201A (en)	2002-02-25
DK1309597T3 (da)	2007-10-22
USRE39251E1 (en)	2006-08-29
NO328500B1 (no)	2010-03-01
CN1269821C (zh)	2006-08-16
SI21100A (sl)	2003-06-30
HRP20030190B1 (en)	2011-07-31
WO2002014323A2 (en)	2002-02-21
AU2001281082B2 (en)	2007-01-04
MXPA03001431A (es)	2004-05-04
CY1107758T1 (el)	2013-06-19
LV13032B (en)	2003-12-20
CA2418109C (en)	2011-09-27
IS6714A (is)	2003-02-11
ATE366735T1 (de)	2007-08-15
WO2002014323A3 (en)	2002-05-02
DE60129334D1 (en)	2007-08-23
US7153879B2 (en)	2006-12-26
GEP20053495B (en)	2005-04-25
PL365610A1 (en)	2005-01-10
CA2418109A1 (en)	2002-02-21
IS2845B (is)	2013-08-15

Publication	Publication Date	Title
JP5046467B2 (ja)	2012-10-10	エポチロンアナログの多形
EP3557998B1 (de)	2023-08-16	Verbindungen, zusammensetzungen und verfahren zur verwendung
AU2001281082A1 (en)	2002-05-23	Polymorphs of an epothilone analog
WO2020117877A1 (en)	2020-06-11	Compounds, compositions and methods of use
AU2021338439A1 (en)	2023-02-23	Novel salts, crystals, and co-crystals
CN111196790A (zh)	2020-05-26	新型紫杉烷类衍生物及其药物组合物和用途
AU2020277881B2 (en)	2025-03-06	Crystalline form of sofpironium bromide and preparation method thereof
JP2006521340A (ja)	2006-09-21	ロシグリタゾン・マレイン酸塩の多形体の製法
EP4467536A1 (de)	2024-11-27	Kristalline form eines schwefelhaltigen isoindolinderivats
BRPI0620526A2 (pt)	2011-11-16	sal de acetato e método para alcançar um efeito em um paciente
HK1052010B (en)	2008-01-25	Polymorphs of an epothilone analog
HK40017092B (en)	2024-04-26	Compouns, compositions and methods of use
HK40017092A (en)	2020-09-18	Compouns, compositions and methods of use
HK40009119A (en)	2020-06-19	Crystal of benzofuran derivative free base and preparation method
HK40009119B (en)	2021-03-05	Crystal of benzofuran derivative free base and preparation method